
Leqembi Launched in China to Fight Alzheimer’s
China is the third country to launch LEQEMBI for sale, to fight Alzheimer’s, following the United States and Japan.
China is the third country to launch LEQEMBI for sale, to fight Alzheimer’s, following the United States and Japan.
Three FDA-Approved drugs, terazosin, doxazosin, and alfuzosin, have a happy side effect; they boost energy production in brain cells. New studies suggest this slows or prevents Dementia with Lewy Bodies.
Grandma hates taking her medications. With her dementia, she ends up asking 10 different times why she has to take it! What should I do?
The unanimous 11-0 FDA vote clears an exciting path for this new Alzheimer’s drug.
South Korea joined other countries in approving LEQEMBI® (generic lecanemab) for mild cognitive impairment, mild and early Alzheimer’s. Learn how Leqembi is treating Alzheimer’s around the world.
“People with dementia living in nursing homes and in the community were prescribed less and we did not detect negative health impacts for these groups.”
LEQEMBI® is the newest Alzheimer’s drug. It is administered in hospitals via IV. Biogen applied to the FDA for approval of a home version using an “Autoinjector”. See how it works and learn its advantages.
The first doses of the newly approved Alzheimer’s drug “Leqembi” were administered in Louisville. More than 100 people have signed up since then. See why.
Biogen reprioritize resources allocated to ADUHELM® to advance LEQEMBI®.
At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that promises to slow the progression of the disease. Only five Alzheimer’s treatments have been approved by the FDA up until a decade ago, and this is only the second to address the progression of the disease.
Empower yourself with a detailed report of your brain’s function, consisting of an assessment of your cognitive function and your brain connectivity with a quick 45-minute on-site appointment.
Kimberly Warnick, Certified Dementia Practitioner and Care Navigator
Selling Alzheimer’s books takes time – buyers rarely commit right away. Smart authors plan for the long game, offering gentle, repeated reminders to buy. No tool does this more effectively or simply than the Alzheimer’s & Dementia Weekly Newsletter service. Keep your book—and its message—at the center of your readers’ attention.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.